B 
Boston Scientific BSX · USD
Health Care · Health Care Equipment & Supplies · US listing · 🇺🇸 United States
S&P 500
44.02
+2.97%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in USD, from our data supplier.
Revenue
$20.07bn
FY2016FY2025
Net income
$2.89bn
FY2016FY2025
Free cash flow
$3.66bn
FY2016FY2025
Shareholders' equity
$24.23bn
FY2016FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $20.07bn | $16.75bn | $14.24bn | $12.68bn | $11.89bn | $9.91bn | $10.73bn | $9.82bn | $9.05bn | $8.39bn |
| Gross profit | $13.85bn | $10.27bn | $8.83bn | $7.71bn | $7.46bn | $5.58bn | $6.88bn | $6.48bn | $5.87bn | $5.34bn |
| Research and development | $2.05bn | $1.61bn | $1.41bn | $1.32bn | $1.20bn | $1.14bn | $1.17bn | $1.11bn | $997.0m | $920.0m |
| Operating income | $3.97bn | $2.63bn | $2.18bn | $1.82bn | $1.92bn | $601.0m | $1.13bn | $1.74bn | $1.16bn | $411.0m |
| Net income | $2.89bn | $1.85bn | $1.59bn | $698.0m | $1.04bn | −$82.0m | $4.70bn | $1.67bn | $104.0m | $347.0m |
| Diluted earnings per share | 1.93 | 1.24 | 1.08 | 0.48 | 0.72 | -0.06 | 3.33 | 1.19 | 0.08 | 0.25 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $43.67bn | $39.40bn | $35.14bn | $32.47bn | $32.23bn | $30.78bn | $30.57bn | $21.00bn | $19.04bn | $18.10bn |
| Cash and short-term investments | $2.04bn | $414.0m | $865.0m | $928.0m | $1.93bn | $1.73bn | $217.0m | $146.0m | $188.0m | $196.0m |
| Total liabilities | $19.20bn | $17.39bn | $15.61bn | $14.90bn | $15.61bn | $15.45bn | $16.69bn | $12.27bn | $12.03bn | $11.36bn |
| Debt | $11.53bn | $10.75bn | $9.10bn | $8.94bn | $9.06bn | $9.14bn | $10.01bn | $7.06bn | $5.62bn | $5.48bn |
| Shareholders' equity | $24.23bn | $21.77bn | $19.28bn | $17.57bn | $16.62bn | $15.33bn | $13.88bn | $8.72bn | $7.01bn | $6.73bn |
| Shares outstanding | 1,496m | 1,490m | 1,477m | 1,442m | 1,436m | 1,441m | 1,413m | 1,406m | 1,373m | 1,381m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | $4.53bn | $3.44bn | $2.50bn | $1.53bn | $1.87bn | $1.51bn | $1.84bn | $310.0m | $1.43bn | $972.0m |
| Capital spending | −$876.0m | −$790.0m | −$800.0m | −$612.0m | −$554.0m | −$376.0m | −$461.0m | −$316.0m | −$319.0m | −$376.0m |
| Free cash flow | $3.66bn | $2.65bn | $1.70bn | $914.0m | $1.32bn | $1.13bn | $1.38bn | −$6.0m | $1.11bn | $596.0m |
| Dividends paid | — | — | −$28.0m | −$55.0m | −$55.0m | −$28.0m | −$28.0m | −$28.0m | −$28.0m | — |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.44bn | $5.20bn | $5.29bn | $5.07bn | $5.06bn | $4.66bn | $4.56bn | $4.21bn |
| Gross profit | $3.85bn | $3.61bn | $3.94bn | $3.54bn | $3.42bn | $2.95bn | $2.67bn | $2.65bn |
| Operating income | $1.18bn | $1.16bn | $1.27bn | $1.03bn | $909.0m | $896.0m | $589.0m | $674.0m |
| Net income | $907.0m | $1.34bn | $668.0m | $755.0m | $793.0m | $674.0m | $566.0m | $469.0m |
| Diluted earnings per share | 0.61 | 0.90 | 0.45 | 0.50 | 0.53 | 0.45 | 0.38 | 0.31 |
| Cash from operations | $1.47bn | $348.0m | $1.36bn | $1.34bn | $1.29bn | $541.0m | $1.46bn | $1.00bn |
| Capital spending | −$195.0m | −$177.0m | −$351.0m | −$181.0m | −$190.0m | −$187.0m | −$293.0m | −$304.0m |
| Free cash flow | $1.28bn | $171.0m | $1.01bn | $1.16bn | $1.10bn | $354.0m | $1.16bn | $698.0m |
| Total assets | $45.22bn | $44.35bn | $43.67bn | $42.71bn | $41.56bn | $40.14bn | $39.40bn | $38.08bn |
| Cash and short-term investments | $539.0m | $1.52bn | $2.04bn | $1.27bn | $534.0m | $725.0m | $414.0m | $2.50bn |
| Debt | $12.50bn | $10.90bn | $11.53bn | $11.60bn | $11.59bn | $11.31bn | $10.75bn | $10.88bn |
| Shareholders' equity | $24.93bn | $25.86bn | $24.23bn | $23.39bn | $22.42bn | $22.21bn | $21.77bn | $20.71bn |
Financial ratios
Data as of 8 Sept 2026
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|
| Gross margin | 69.0% | 61.3% | 62.0% | 60.8% | 62.8% | 56.2% |
| Operating margin | 19.8% | 15.7% | 15.3% | 14.4% | 16.2% | 6.1% |
| Net margin | 14.4% | 11.1% | 11.2% | 5.5% | 8.7% | -0.8% |
| Return on equity | 11.9% | 8.5% | 8.3% | 4.0% | 6.3% | -0.5% |
| Return on assets | 6.6% | 4.7% | 4.5% | 2.1% | 3.2% | -0.3% |
| Free cash flow yield | 7.6% | 5.9% | 4.7% | 3.1% | 3.5% | 2.7% |
| Revenue growth | 19.9% | 17.6% | 12.3% | 6.7% | 19.9% | -7.7% |
| Earnings growth | 55.7% | 16.4% | 128.2% | -32.9% | -1368.3% | -101.7% |
| Current ratio | 1.62x | 1.08x | 1.32x | 1.51x | 1.48x | 1.82x |
| Debt to equity | 0.48x | 0.49x | 0.47x | 0.51x | 0.54x | 0.60x |
| Equity ratio | 55.5% | 55.3% | 54.9% | 54.1% | 51.6% | 49.8% |
| Interest coverage | 11.38x | 6.81x | 8.02x | 3.93x | 5.51x | 1.28x |
| R&D as a share of sales | 10.2% | 9.6% | 9.9% | 10.4% | 10.1% | 11.5% |
| Buybacks as a share of market value | -0.4% | -0.9% | -2.4% | -0.4% | 0.3% | -1.9% |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 16.5% | 15.2% | 10.4% |
| Operating income | 29.6% | 45.9% | 17.5% |
| Net income | 60.5% | — | — |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Gross margin | 65.5% | 63.8% | 62.8% | 63.2% |
| Operating margin | 17.9% | 16.6% | 15.4% | 14.0% |
| Net margin | 12.9% | 11.0% | 9.3% | 11.1% |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings | 49.4 | 71.8 | 53.6 | 95.6 | 58.7 | -631.6 | 13.6 | 29.7 | 327.4 | 86.1 |
| Price to sales | 7.1 | 8.0 | 6.0 | 5.3 | 5.1 | 5.2 | 6.0 | 5.1 | 3.8 | 3.6 |
Market value over time
31 Oct 2016 to 4 Sept 2026, in USD
$30.36bn$70.98bn
Share price return
Finished calendar years
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Return | 9% | 58% | 22% | 16% | 13% | -23% | 36% | 31% | 18% | 20% |
Dividends and splits
Per share, in the currency the company pays
Paid for 0 years.
- 2-for-1 split · 6 Nov 2003
- 2-for-1 split · 1 Dec 1998
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.